Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
NRG Oncology
City of Hope Medical Center
M.D. Anderson Cancer Center
City of Hope Medical Center
University of California, San Francisco
Centre Francois Baclesse
NeuGATE Theranostics
M.D. Anderson Cancer Center
University of Texas Southwestern Medical Center
Zhongnan Hospital
OHSU Knight Cancer Institute
Mahidol University
City of Hope Medical Center
Zhejiang Provincial People's Hospital
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
State University of New York - Upstate Medical University
National Cancer Institute (NCI)
Nanobiotix
NYU Langone Health
UNC Lineberger Comprehensive Cancer Center
University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center
NYU Langone Health
National Cancer Institute (NCI)
Swiss Cancer Institute
Barts & The London NHS Trust
Wake Forest University Health Sciences
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Taizhou Hospital
Azienda Ospedaliero-Universitaria Careggi
Dana-Farber Cancer Institute
AHS Cancer Control Alberta
AHS Cancer Control Alberta
AHS Cancer Control Alberta
University of Michigan Rogel Cancer Center
Tata Memorial Hospital
Jiangsu Cancer Institute & Hospital
Children's Oncology Group
Mayo Clinic
AHS Cancer Control Alberta
AHS Cancer Control Alberta
Universitair Ziekenhuis Brussel